These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31971477)

  • 1. Designer benzodiazepines' pharmacological effects and potencies: How to find the information.
    El Balkhi S; Monchaud C; Herault F; Géniaux H; Saint-Marcoux F
    J Psychopharmacol; 2020 Sep; 34(9):1021-1029. PubMed ID: 31971477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer.
    El Balkhi S; Chaslot M; Picard N; Dulaurent S; Delage M; Mathieu O; Saint-Marcoux F
    Int J Legal Med; 2017 Jul; 131(4):979-988. PubMed ID: 28160051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
    Bäckberg M; Pettersson Bergstrand M; Beck O; Helander A
    Clin Toxicol (Phila); 2019 Mar; 57(3):203-212. PubMed ID: 30348014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.
    Brunetti P; Giorgetti R; Tagliabracci A; Huestis MA; Busardò FP
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34208284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
    Carpenter JE; Murray BP; Dunkley C; Kazzi ZN; Gittinger MH
    Clin Toxicol (Phila); 2019 Apr; 57(4):282-286. PubMed ID: 30430874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flubromazolam--A new life-threatening designer benzodiazepine.
    Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Zielińska-Psuja B; Panieński P; Żaba C
    Clin Toxicol (Phila); 2016; 54(1):66-8. PubMed ID: 26585557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK.
    Abouchedid R; Gilks T; Dargan PI; Archer JRH; Wood DM
    J Med Toxicol; 2018 Jun; 14(2):134-143. PubMed ID: 29671244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing prevalence of designer benzodiazepines in impaired driving: A 5-year analysis from 2017 to 2021.
    Papsun DM; Chan-Hosokawa A; Lamb ME; Logan B
    J Anal Toxicol; 2023 Nov; 47(8):668-679. PubMed ID: 37338191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood concentrations of new designer benzodiazepines in forensic cases.
    Høiseth G; Tuv SS; Karinen R
    Forensic Sci Int; 2016 Nov; 268():35-38. PubMed ID: 27685473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases.
    Pettersson Bergstrand M; Richter LHJ; Maurer HH; Wagmann L; Meyer MR
    Drug Test Anal; 2019 Jan; 11(1):45-50. PubMed ID: 29996009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designer Benzodiazepines' Activity on Opioid Receptors: A Docking Study.
    Catalani V; Botha M; Corkery JM; Guirguis A; Vento A; Schifano F
    Curr Pharm Des; 2022; 28(32):2639-2652. PubMed ID: 35538798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of an LC-MS/MS Method for the Quantification of 13 Designer Benzodiazepines in Blood.
    Mei V; Concheiro M; Pardi J; Cooper G
    J Anal Toxicol; 2019 Oct; 43(9):688-695. PubMed ID: 31436813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects.
    Edinoff AN; Nix CA; Odisho AS; Babin CP; Derouen AG; Lutfallah SC; Cornett EM; Murnane KS; Kaye AM; Kaye AD
    Neurol Int; 2022 Aug; 14(3):648-663. PubMed ID: 35997362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques.
    Mullin A; Scott M; Vaccaro G; Floresta G; Arillotta D; Catalani V; Corkery JM; Stair JL; Schifano F; Guirguis A
    Pharmacy (Basel); 2024 Jan; 12(1):. PubMed ID: 38251407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probe Electrospray Ionization Tandem Mass Spectrometry for the Detection and Quantification of Benzodiazepines.
    Griffeuille P; El Balkhi S; Dulaurent S; Saint-Marcoux F
    Ther Drug Monit; 2024 Aug; 46(4):522-529. PubMed ID: 38498915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analytical strategy for designer benzodiazepines and Z-hypnotics determination in plasma samples using ultra-high performance liquid chromatography/tandem mass spectrometry after microextraction by packed sorbent.
    Ares-Fuentes AM; Lorenzo RA; Fernández P; Carro AM
    J Pharm Biomed Anal; 2021 Feb; 194():113779. PubMed ID: 33279303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent findings and advancements in the detection of designer benzodiazepines: a brief review.
    Wu D; Fu L
    Arh Hig Rada Toksikol; 2022; 74(4):224-231. PubMed ID: 38146763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
    Orsolini L; Corkery JM; Chiappini S; Guirguis A; Vento A; De Berardis D; Papanti D; Schifano F
    Curr Neuropharmacol; 2020; 18(9):809-837. PubMed ID: 31933443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designer benzodiazepine dependence and the difficulties of outpatient management; a case report.
    Reeves JJ; Brown AD; Collier BS
    J Addict Dis; 2024; 42(1):75-79. PubMed ID: 36112384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.